FDA approves Zynyz for advanced anal cancer, marking a breakthrough for the 10,000 diagnosed annually—including actress ...

Author Julia DeVillers was daignosed with anal cancer and as it progresses, she was told she had 48 hours to live. Her ...

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

ANAL cancer rates have been rising globally – and now scientists have identified a group of people most at risk. Since the ...

White women over 65 experienced the most significant increase, with rates climbing 4.3% annually to reach 11.4 cases per ...

With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an ...

A kinder treatment for anal cancer involving a lower dose and shorter course of radiotherapy is more effective than ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

These findings highlight specific patient groups who may benefit from targeted screening for anal HPV and anal cancer,” said lead study author Dr. Ashley Robinson.

PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

Cases of anal cancer have been rising significantly across the world, with doctors being able to identify who is at the most ...